NCT05321095

Screening for Albuminuria at the First Line for Early Identification of CKD

Screening for Albuminuria at the First Line for Early Identification of Chronic Kidney Disease: a Pilot Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 141 (actual)
• Sponsor: General Practitioners Research Institute · Network
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Early detection of kidney disease

Detailed description

Early detection and appropriate treatment of kidney disease is important as this may prevent future cardiovascular complications and end-organ damage more effectively than intervention in more advanced stages of disease. There is a well-established relationship between albuminuria and renal- and cardiovascular disease. Elevated albuminuria has a relatively high prevalence in the general population (5-9%). The prevalence of albuminuria is even higher in high-risk patients with diabetes Mellitus, hypertension, obesity, cardiovascular disease and lipid disorders. Adequate treatment of albuminuria, preferable at early stages can prevent both cardiovascular and renal disease progression. However, scarce epidemiological data show that albuminuria measurements are only conducted in a minority of individuals and disease recognition is suboptimal, even in high-risk groups. The current study aims to evaluate if and how early identification of chronic kidney disease by targeted screening of albuminuria levels is feasible in primary care (pharmacies and general practitioners) to optimally discover and treat patients with elevated albuminuria.

Conditions

• Chronic Kidney Diseases
• Albuminuria

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Albuminuria test	During participation, subjects are asked to collect one or more urine samples for albuminuria determination.
DIAGNOSTIC_TEST	HbA1c test	During the screening visit, HbA1c will be measured with a point-of-care test (Affinion HbA1c, Abbott).
DIAGNOSTIC_TEST	Creatinine test	During the screening visit, creatinine will be measured with a point-of-care test (i-STAT Alinity handheld analyser, Abbott).

Timeline

• Start date: 2021-11-25
• Primary completion: 2023-12-31
• Completion: 2024-07-30
• First posted: 2022-04-11
• Last updated: 2024-08-09

Locations

1 site across 1 country: Netherlands